Advertisement
This unique new drug is also known as compound NIAID #11039 and hasreceived a patent from the United States with patent number: 6,821,958 onNovember 23, 2004. Also, the World International Patent Organization publishedthe International Application Number as PCT/US2005/039528 on November 5, 2006.
Advertisement
Dr. Hershline hosted Session V at the World Aids Day Conference China fromDecember 1 to December 3, 2006, to initially present LiSAVIOR.
The proposed roadblock to cure HIV is that current drug and vaccinationtreatments do not treat the growth of HIV in the gastrointestinal tract. HIVvirus multiplies and mutates in the gastrointestinal tract and then isreabsorbed into the blood. This process is known to occur when HIV infectionresults from the use of contaminated needles or during sexual intercourse. Thegastrointestinal tract is comprised of the mouth and its structures, thepharynx, the esophagus, the stomach, the small intestines, the largeintestines and the anus.
The proposed solution to overcome this roadblock is the oral clinical useof LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIORblocks not only viral entry into cells but also cell-to-cell transfer of thevirus. LiSAVIOR is proposed to be used alone or with any known HIV drug andvaccine therapy.
Pre-clinical efficacy testing of LiSAVIOR has shown that the effectiveconcentration of LiSAVIOR is found to be equivalent to diluting a 1% solutionof LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powderthat is stable at room temperature and humidity.
"I am thinking in terms of problem solving. Traditional commercial drugdesign and projects funding from the NIH has completely ignored this approachto date," stated Dr. Hershline. "I think we have to talk in terms of a curefor HIV. I want to cure HIV and that is why my foundation is calledCureHIV.us," concluded Dr. Hershline.
Dr. Hershline is hopeful that Bill and Melinda Gates and their GlobalInitiative funding looks into the work and progress that he has made towardssolving this problem and fills the gap in funding.
Dr. Hershline has a doctorate degree in drug design and a medical degree.Pre-clinical development of LiSAVIOR has been twenty years in the making.Despite the critical need for such a unique and potentially life savinginvention, LiSAVIOR remains completely un-funded.
Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thruCureHIV.us Headquarters by email: [email protected], mail P.O. Box 23467,Hilton Head Is., SC, 29925, by fax: +1-843-342-5924, phone: +1-843-342-5900.Direct to Dr. Hershline: +1-843-683-3683.
Web site: http://www.curehiv.us
SOURCE CureHIV.us
